Next Article in Journal
Microencapsulation of Fluticasone Propionate and Salmeterol Xinafoate in Modified Chitosan Microparticles for Release Optimization
Next Article in Special Issue
Tackling Resistance to Cancer Immunotherapy: What Do We Know?
Previous Article in Journal
Napthrene Compounds from Mycelial Fermentation Products of Marasmius berteroi
Previous Article in Special Issue
Role of the Neutrophil in the Pathogenesis of Advanced Cancer and Impaired Responsiveness to Therapy
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Molecules
Volume 25
Issue 17
10.3390/molecules25173900
Review Report
molecules-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
Review
Peer-Review Record

Interaction between Immunotherapy and Antiangiogenic Therapy for Cancer

Molecules 2020, 25(17), 3900; https://doi.org/10.3390/molecules25173900
by Koichi Furukawa, Tatsuya Nagano *, Motoko Tachihara, Masatsugu Yamamoto and Yoshihiro Nishimura
Reviewer 1: Anonymous
Reviewer 2: Anonymous
Molecules 2020, 25(17), 3900; https://doi.org/10.3390/molecules25173900
Submission received: 27 July 2020 / Revised: 23 August 2020 / Accepted: 25 August 2020 / Published: 26 August 2020
(This article belongs to the Special Issue The Future of the Cancer Treatment: The Immunotherapy Next Generation)

Round 1

Reviewer 1 Report

In this paper, Koichi Furukawa et al., made a review related with the Interaction between immunotherapy and antiangiogenic therapy for cancer.

The subject of the article are actual. However the synergistic mechanisms referred in the abstract by the auhtors is not well described in the text. They need to clarify this aspect. Further, they need to describe and clarify also the role of immunoscore.

Furthermore, the conclusion need to be improved

Other comments:

  1. The text need to be illustrated with same figures (for instance related with TIME and cancer immunity cycle) and the table 1 aspect needs to be modified in order to be easy to read and more appealing.

Author Response

Please see the attachment.

Author Response File: Author Response.docx

Reviewer 2 Report

The review describes the molecular and clinical aspects of the immunotherapy (i.e. immune checkpoint inhibitors - ICIs) and antiangiogenic therapy. Chapter # 3 illustrates an important regulatory role of the tumor microenviroment in the tumor response to ICIs. To my opinion, it's very important and provides the molecular basis for the rationale to use the ocombination therapy of ICIs and antiangiogenic drugs for cancer patients.

In general, the review is very well-wrtten, the language and style are also very good. 

Minor: 

Just a suggestion - given the interaction between VEGF and immune system is complex and includes the multiple mechanisms (e.g.  upregulation of PD-1 on CD8 lymphocytes, maturation of DCs, activity of Tregs, polarization of the macrophages from M1 to M2, etc.), it will be great to include the figure in the manuscript to illustrate these interactions. This practics is very common, especially for the reviews. This figure will be very helpful and illustrative and convince a broad audience that inhibition of VEGF-signaling will have a strong impact on the effectiveness of immunotherapy for the patients with solid tumors.  

Author Response

Please see the attachment.

Author Response File: Author Response.docx

Back to TopTop